Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Respiratorius

1.73 SEK

+4.55 %

Less than 1K followers

RESP

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+4.55 %
-8.97 %
-52.08 %
-78.38 %
-73.46 %
-53.13 %
-96.46 %
-99.03 %
-87.95 %

Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was originally established in 1999 as a spin-off from Lund University. The business is located in Sweden, where research is conducted in-house but also through international partners. The company is headquartered in Lund.

Read more
Market cap
13.63M SEK
Turnover
5.38K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release9/1/2025, 6:32 AM

Respiratorius Receives Meeting Minutes from FDA Pre-IND Meeting

Respiratorius
Regulatory press release8/12/2025, 6:30 AM

Respiratorius has conducted a pre-IND meeting with the FDA

Respiratorius
Regulatory press release6/18/2025, 6:18 AM

Respiratorius Granted Pre-IND Meeting with FDA for VAL001

Respiratorius

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release5/27/2025, 12:33 PM

Respiratorius: Notice of Allowance for European Patent on VAL001 Formulation

Respiratorius
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.